



Contents lists available at ScienceDirect

European Journal of Pain

journal homepage: [www.EuropeanJournalPain.com](http://www.EuropeanJournalPain.com)

## Review

## Use of oral ketamine in chronic pain management: A review

Maren I. Blonk<sup>a</sup>, Brigitte G. Koder<sup>b</sup>, Patricia M.L.A. van den Bemt<sup>a,c</sup>, Frank J.P.M. Huygen<sup>b,\*</sup><sup>a</sup> Department of Hospital Pharmacy, Erasmus Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands<sup>b</sup> Department of Anaesthesiology, Erasmus Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands<sup>c</sup> Utrecht Institute for Pharmaceutical Sciences, Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht University, P.O. Box 80 082, 3508 TB Utrecht, The Netherlands

## ARTICLE INFO

## Article history:

Received 29 June 2009

Received in revised form 31 August 2009

Accepted 20 September 2009

Available online xxx

## Keywords:

Chronic pain

Ketamine

Oral administration

Neuropathic pain

Review

## ABSTRACT

The analgesic effect of ketamine is primarily based on the antagonism of the *N*-methyl-*D*-aspartate (NMDA) receptor. Activation of NMDA receptors may play a crucial role in the pathogenesis of chronic pain. Little formal research has been performed on the efficacy and safety of ketamine in chronic pain, especially concerning long-term oral administration. This review provides an overview of the available clinical data on the use of oral ketamine in chronic pain management. A literature search was performed in MEDLINE, EMBASE and the Cochrane Library, resulting in 22 relevant articles. Because most retrieved articles were of a descriptive nature (e.g. case reports and case series) a quantitative analysis was not possible. There was no consistent dose–response relation. A recommended starting dosage in ketamine-naïve patients is 0.5 mg/kg racemic ketamine or 0.25 mg/kg *S*-ketamine as a single oral dose. The dosage is increased by the same amount if required. For a continuous analgesic effect it is usually given 3–4 times daily. The injection fluid can be taken orally. When parenteral ketamine is switched to oral administration the daily dosage can be kept equal and, depending on clinical effect and/or adverse effects, is slowly increased. The pharmacologically active metabolite norketamine is believed to contribute to the analgesic effect of oral ketamine. Lack of evidence regarding efficacy, and the poor safety profile, do not support routine use of oral ketamine in chronic pain management. Oral ketamine may have a limited place as add-on therapy in complex chronic pain patients if other therapeutic options have failed.

© 2009 European Federation of International Association for the Study of Pain Chapters. Published by Elsevier Ltd. All rights reserved.

## 1. Introduction

Ketamine is a phencyclidine anaesthetic, increasingly used in subanaesthetic doses as an analgesic in a wide range of pain settings (Visser and Schug, 2006). The analgesic effect of ketamine is primarily based on the antagonism of the *N*-methyl-*D*-aspartate (NMDA) receptor (Fisher et al., 2000). Activation of NMDA receptors results in central sensitization, which may play a crucial role in the pathogenesis of chronic pain (Bennett, 2000; Eide, 2000). Besides acting on the NMDA receptor, ketamine also acts on nicotinic, muscarinic and opioid receptors (Jensen et al., 2008). Ketamine both has an anti-nociceptive and anti-hyperalgesic effect, the latter especially occurring in the lower dosage ranges (Persson 2008).

Administration of ketamine is reported to reduce pain in patients with neuropathic pain of various origins, including postherpetic neuralgia (Eide et al., 1995), complex regional pain syndrome (CRPS) (Kiefer et al., 2008), cancer pain (Mercadante et al., 2000; Okon, 2007), orofacial pain (Mathisen et al., 1995) and phantom limb pain (Eichenberger et al., 2008). It is commercially available

as injection solution containing a 1:1 racemic mixture of ketamine or the *S*-ketamine isomer. *S*-ketamine is approximately twice as potent in analgesia as the racemic mixture of ketamine (Arendt-Nielsen et al., 1996). Literature is not conclusive about the differences in safety profiles of ketamine as racemic mixture and *S*-ketamine (Kohrs and Durieux, 1998). When used in chronic pain management routes of administration include parenteral (intravenous, subcutaneous, intramuscular, epidural, intra-articular), oral, topical, intranasal and sublingual (Kronenberg, 2002; Hocking and Cousins, 2003; Visser and Schug, 2006; Ben-Ari et al., 2007). In long-term use oral administration is preferred. Orally administered ketamine undergoes extensive first-pass metabolism in the liver, resulting in a bioavailability of approximately 16% (Grant et al., 1981; Clements et al., 1982). The primary metabolic pathway involves hepatic *N*-demethylation via the cytochrome P450 system to form norketamine, a pharmacologically active metabolite (White et al., 1982). Oral administration of ketamine is associated with higher serum levels of norketamine compared to other routes of administration (Grant et al., 1981; Clements et al., 1982). The elimination half-life is 2–3 h for ketamine (Grant et al., 1981) and approximately 4 h for norketamine (Product information leaflet, 1999). Norketamine is thought to contribute to the analgesic effect and the duration of effect after oral administration of ketamine

\* Corresponding author. Tel.: +31 10 7034906; fax: +31 10 7035184.

E-mail address: [f.huygen@erasmusmc.nl](mailto:f.huygen@erasmusmc.nl) (F.J.P.M. Huygen).

(White et al., 1982; Ebert et al., 1997; Holtman et al., 2008). Although the use of ketamine as an analgesic is now generally accepted, the evidence base remains poor. Little formal research has been performed on the efficacy and safety of ketamine in chronic pain management, especially concerning long-term oral administration. Oral formulations of ketamine are not commercially available. The parenteral formulation is given as an oral solution or an extemporaneous preparation is made. In general, off-label use of medication has to be based on evidence about efficacy and safety.

The aim of this review is to provide an overview of the available evidence regarding the efficacy and safety of oral ketamine in chronic pain management.

## 2. Methods

A literature search for this review was performed in the MEDLINE database from 1966 to March 2009, the EMBASE database from 1950 to March 2009 and the Cochrane Library in February 2009. Keywords or MeSH terms used in the search strategy were: 'ketamine', 'administration, oral', 'chronic pain', 'pain', 'neuropathic pain', 'cancer pain'. The keywords with 'pain' were separated using the word 'OR'. Articles describing a study based on animal research and research about acute postoperative pain were excluded by entering the term 'NOT' in the search strategy. Furthermore, the search option 'related articles' in MEDLINE was used. The titles and abstracts obtained from the search were assessed for relevance.

To be included the article had to meet the following criteria: (1) the study is performed in adults, (2) ketamine or S-ketamine is administered orally as an analgesic, (3) the indication of ketamine is chronic pain, (4) ketamine treatment is evaluated, (5) the article is written in English, and (6) it is an original article (duplicates and reviews are excluded). There was no restriction on the type of report or the design of the study. Case reports and short communications were also included. In addition, a secondary search was performed by handsearching the reference lists from the collected reviews and relevant articles.

The articles were analysed by two reviewers. They collected information about the number of included patients receiving oral ketamine, study design, pain type, dosage regimen, efficacy and adverse effects. The methodological quality of the individual studies was rated according to the classification levels presented in Table 1 (Hocking and Cousins, 2003).

## 3. Results

### 3.1. Literature search

With the literature search we identified 88 articles. Seven duplicates could be removed. Based on the inclusion and exclusion criteria another 57 articles were withdrawn. Additional searching in the reference lists of the related articles and reviews resulted in the identification of two extra articles. After reviewing the full text of the remaining 26 articles, 22 articles could be included in our review. The literature selection procedure and reasons for exclusion

are shown in Fig. 1. Table 2 lists the 22 included studies and provides information about each study in order of methodological quality, followed by publication date. Due to the small number of trials and patients, and the heterogeneity of data, it was not possible to perform a quantitative analysis. Most retrieved articles were of a descriptive nature, such as case reports and case series. The comparative trials that were relevant in this review included small numbers of patients with a variety of study objectives, designs and outcome measurements. None of the included studies had a high-quality methodological design. Of the 22 included studies, 16 were non-comparative observational studies or anecdotal reports about oral ketamine. Four of those were case series and 12 were case reports. The remaining six published reports describe comparative studies in which oral ketamine is studied as add-on therapy with morphine (Lauretti et al., 1999) or compared to placebo (Eide and Stubhaug, 1997; Nikolajsen et al., 1997; Haines and Gaines, 1999; Rabben et al., 1999; Furuhashi-Yonaha et al., 2002). Two of the comparative studies are *N* of 1 trials in which one patient re-




Fig. 1. Overview of the literature search and selection procedure.

**Table 1**  
Classification of the methodological quality of the included publications.

|     |  |
|-----|--|
| I   | Systematic review (meta-analysis)  |
| II  | Randomized double-blind controlled trials of sufficient size and consistency   |
| III | Randomized clinical trial of moderate quality or insufficient size or other comparative trials (non-randomized, cohort studies, crossover studies) |
| IV  | Non-comparative trial, observational study, case series, comparative trial with one patient ( <i>N</i> of 1 trial)                                 |
| V   | Case report  |

**Table 2**

Published reports concerning oral administration of ketamine in chronic pain.

| Study                          | Number of patients | Design (quality) <sup>a</sup> | Pain type   | Oral ketamine  |  | Outcomes   |  |
|--------------------------------|--------------------|-------------------------------|---|--|--|--|--|
|                                |                    |                               |   | Daily dosage/<br>number of divided doses   | Duration of treatment                          | Efficacy   | Adverse effects  |
| Rabben et al. (1999)           | 26                 | CO, PC, SB (III)              | Secondary trigeminal neuralgia                            | 4 mg/kg/1 (at night) after KET IM 0.4 mg/kg vs. pethidine 1.0 mg/kg single dose  | 3 days   | Five patients significant but variable pain relief. Non-responders to KET IM no response to KET PO.  | Dizziness, sedation, dry mouth, blurred vision, altered hearing, sensory illusions     |
| Haines and Gaines (1999)       | 21                 | CO, PC (III)                  | Neuropathic pain  | 20 up to 100 mg/1 (dose escalation), average 45 mg/1 (PC)  | 1 week (run-in) + 3 × 1 week KET vs. 1 week PL | 10/21 withdrew after run-in open-dose escalation period due to SE. 9/21 entered PC study. 3/9 patients reported to have benefit from KET   | Light headedness, dizziness, tiredness, headache, nervous floating feeling, bad dreams |
| Lauretti et al. (1999)         | 15                 | RCT (III)                     | Chronic cancer pain                                       | 1 mg/kg/2 (patients randomized to one of 4 groups (N = 15): morphine (control), morphine + KET PO, + nitroglycerin or + dipyron) | 1 month  | After day 15 daily morphine consumption was statistically significant reduced in KET-group due to analgesic and/or opioid-sparing effect   | Hallucinations; less somnolence compared to control group                              |
| Furuhashi-Yonaha et al. (2002) | 8                  | CO, PC (III)                  | Neuropathic pain (CRPS, phantom pain, PHN, visceral pain) | 2 mg/kg/4, in long-term treatment 25–136 mg per day (positive response to KET IV test-dose)                                      | 1 week, in long-term treatment 9–54 months     | Statistically significant reduction of VAS score (average 30%) after 1 week of. 4/8 patients received long-term treatment. No tolerance    | Nightmares and dizziness, headache   |
| Nikolajsen et al. (1997)       | 1                  | N1, PC (IV)                   | Post-amputation stump pain                                | 200 mg/4 (also KET IV 0.42 mg/kg single dose (vs. PL DB))  | 3 months                                       | KET PO 50 mg (vs. PL SB) gave complete pain relief in 10 min and lasted up to 6 h. Ongoing pain relief when four times daily. No tolerance | No AE  |
| Eide and Stubhaug (1997)       | 1                  | N1, PC, DB (IV)               | Glossopharyngeal neuralgia                                | 360 mg/6 (KET IV 0.065 mg/kg; optimal PO dose was found in open-dose escalation trial)   | 10 × 2 days                                    | Statistically significant pain relief in VAS scores by KET PO in 8/10 treatment periods  | Fatigue, dizziness   |
| Enarson et al. (1999)          | 21                 | CS, R (IV)                    | Central and peripheral neuropathic pain                   | 100 mg, adjusted to 40–500 mg (average 220 mg)/number of divided doses not mentioned   | <10 days up to > 1 year                        | 7/21 ↓ pain. 3/7 responders continued in long-term treatment   | Dissociative feeling, somnolence, insomnia, sensory changes                            |
| Rabben and Oye (2001)          | 13                 | CS (IV)                       | Neuropathic orofacial pain                                | 4 mg/kg/1 (at night) (after KET IM 0.4 mg/kg test-dose)  | 3 days   | 8/13 patients reduced pain intensity or complete analgesia   | Anxiety and hallucinations, 'near death' experience, dizziness                         |
| Kannan et al.(2002)            | 9                  | CS (IV)                       | Neuropathic cancer pain                                   | 1.5 mg/kg (adjusted 70 mg average)/3   | 2 months                                       | Mean NRS ↓ of 3.6 (±1.5) points after 24 h. In 7/9 patients continuous ↓ by ≥3 points. No tolerance was observed                           | Anorexia, nausea, vomiting, sedation. 3/9 stopped due to AE                            |
| Cvrcek (2008)                  | 32                 | CS (IV)                       | PHN and diabetic polyneuropathy                           | 150 mg/5 (initial KET IV single dose)  | 3 months                                       | Statistically significant ↓ of VAS score   | Dizziness, dry mouth, sedation, nausea, euphoria, memory deterioration                 |
| Hoffmann et al. (1994)         | 1                  | CR (V)                        | Ophthalmic PHN  | 3 mg/kg (240 mg)/6, up to 12.5 mg/kg (1000 mg)/5 (KET IM bolus 0.2 mg/kg and SC 0.06 mg/kg/h followed by PO)                     | 5 weeks  | Pain relief. Other analgesics were decreased. KET was stopped with no recurrence of pain after 5 weeks                                     | Local inflammation SC infusion site. No AE PO treatment                                |

(continued on next page)

Table 2 (continued)

| Study                            | Number of patients | Design (quality) <sup>a</sup> | Pain type  | Oral ketamine   |                          | Outcomes  |  |
|----------------------------------|--------------------|-------------------------------|--|---|--------------------------|---|--|
|                                  |                    |                               |  | Daily dosage/<br>number of divided<br>doses   | Duration of<br>treatment | Efficacy  | Adverse effects  |
| Broadley et al. (1996)           | 2                  | CR (V)                        | Axonal sensorimotor neuropathy                                   | 2.4 mg/kg (150 mg)/3, up to 13 mg/kg (800 mg)/4   | 2 weeks + 1 month        | Pain free at KET SC 4.8 mg/kg/day followed by PO. Worsening of pain after withdrawal of KET<br>Daily dose increased until pain free for 3 months when symptoms returned. After switching to other analgesic back on KET PO and remained pain free for >4 months | Vivid dreams. Inflammation at needle side with KET SC<br>No AE                           |
|                                  |                    |                               | Central neuropathic pain with sympathetic dependent pain         | 0.9 mg/kg (75 mg)/3, up to 5.7 mg/kg (400 mg)/4   | 3 + 4 months             |   |  |
| Klepstad and Borchgrevink (1997) | 1                  | CR (V)                        | PHN  | 300 mg/6 (after using KET IV, SC (100 mg/24 h) and IM 10 mg/day switch to KET PO)             | 2 months                 | Good pain relief. After recurrence of gastric ulcer switched back to KET IM with adequate pain relief   | Headache, nausea, abdominal pain, recurrence of gastric ulcer (relation to KET unclear)  |
| Fisher and Hagen (1999)          | 1                  | CR (V)                        | Neuropathic pain of spinal origin                                | 30 mg/3, up to 75 mg/3 (after 120 mg/24 h SC)   | 5 months                 | Continuous pain relief after switching to PO  | No AE with PO treatment  |
| Friedman et al. (2000)           | 1                  | CR (V)                        | Cancer pain  | Single dose of 75 mg  |                          | Patient was temporarily pain free   | Visual hallucinations and paranoid ideation  |
| Vick and Lamer (2001)            | 1                  | CR (V)                        | Central post-stroke pain   | 0.7 mg/kg (50 mg)/1, up to 2.1 mg/kg (150 mg)/3 (KET IV (total 0.3 mg/kg) followed by KET PO) | 9 months                 | Pain relief, reduced allodynia and hyperalgesia Opioid-sparing effect. Worsening of pain after withdrawal of KET. No evidence of tolerance  | No AE (with prophylactic use of diazepam). Dysphoria, confusion, depression at high dose |
| Fitzgibbon et al. (2002)         | 3                  | CR (V)                        | Neuropathic, ischemic and mixed pain (predominantly neuropathic) | 30–225 mg/3 (KET SC/IV followed by PO adjusted to an effective dose)                          | 3 weeks–6 months         | Pain relief (↓ VAS score). In 2/3 patients opioid reduction possible  | No AE with prophylactic use of hypnotic drugs, inflammation at SC site                   |
| Kapur and Friedman (2002)        | 2                  | CR (V)                        | RLS and neurogenic claudication                                  | 60–80 mg/2  | 6 months and > 1 month   | Pain relief (↓ VAS score with 4–5 points), improvement of RLS symptoms  | No AE  |
| Benitez-Rosario et al. (2003)    | 4                  | CR (V)                        | Neuropathic pain   | 150–375 mg/3 (KET SC, followed by KET PO titrated up to effective dose)                       | 3–5 weeks                | Marked pain relief (assessed by VAS)  | Minor and transitory mental AE in one patient  |
| Sakai et al. (2004)              | 1                  | CR (V)                        | Pain and allodynia associated MS                                 | 20 mg/1 up to 40 mg/2 (after KET IV 15 mg test-dose)  | >1 year                  | KET PO was more effective than dextromethopphan (average ↓ VAS score by >5 points). Positive effect on quality of life  | Some dizziness   |
| Villanueva-Perez et al. (2007)   | 1                  | CR (V)                        | CRPS I   | 90 mg/3, up to 240 mg/4   | >5 months                | Reduction of pain (↓ VAS score by 4–5 points) with concurrent use of other analgesics. Slight progression of pain after 4–5 months  | Nausea and vomiting (controlled with haloperidol)  |
| Okon (2007)                      | 1                  | CR (V)                        | Complex nociceptive-neuropathic pain                             | 60 mg/3, down to 30 mg/2  | >4 months                | Pain relief and decrease in opioid consumption. Worsening of pain after stop of KET PO  | Somnolence, no AE after dose reduction   |

Abbreviations: AE = adverse effects, CO = crossover, CR = case report, CRPS = complex regional pain syndrome, CS = case series, DB = double-blind, IM = intramuscular, IV = intravenous, KET = ketamine (racemic mixture), MPQ = McGill pain questionnaire, MS = multiple sclerosis, N1 = N of 1 trial, NRS = numeric rating score, PC = placebo-controlled, PHN = postherpetic neuralgia, PL = placebo, PO = per os, PPT = pressure-pain threshold, R = retrospective, RCT = randomized controlled trial, RLS = restless legs syndrome, SB = single-blind, SC = subcutaneous, VAS = visual analogue scale.

<sup>a</sup> Classification of methodological quality (Table 1).

ceives both the study drug and a placebo (Eide and Stubhaug, 1997; Nikolajsen et al., 1997). Three of the four remaining compar-

ative studies have a crossover placebo-controlled design in which all participants receive all the interventions. The 22 studies

describe a total of 166 patients receiving oral ketamine in the period 1994 up to 2008. The chronic pain patients had a broad range of pain types. In most cases the pain was diagnosed as neuropathic pain or as having a neuropathic component (for pain types: see Table 2).

### 3.2. Dosage, dosage form and efficacy of oral ketamine

In the non-comparative studies or anecdotal reports (classes IV and V) two approaches to pain treatment with oral ketamine were described. Either the patient started directly with oral ketamine with a low daily dose which, based on clinical effect and/or adverse effects, is increased. Or, the patient started with parenteral ketamine, either a single test dose or continuous treatment with usually intravenous or subcutaneous ketamine, after which the patient is switched to an equipotent oral dose of ketamine. The effective daily dosages ranged from (approximately) 45 mg to 1000 mg. There was no consistent dose–response relation. In the case reports the ratio between equianalgesic potency of ketamine subcutaneous/ketamine per os in daily dose ranged from 1:0.3 to 1:8.5, with a median of 1:1 (Hoffmann et al., 1994; Broadley et al., 1996; Klepstad and Borchgrevink, 1997; Fisher and Hagen, 1999; Fitzgibbon et al., 2002; Benitez-Rosario et al., 2003). The number of divided doses necessary for continuous analgesic effect also ranged from once daily up to a frequency of 6 times daily (on average 3–4 times daily). The duration of effect after a single dose (if there was any effect) ranged from a few hours to 24 h or more. In all the included studies, only the racemic mixture of ketamine was administered. Ketamine was primarily ingested as an oral liquid. Usually the injection fluid was used, in some cases mixed with fruit juice or syrup to mask the bitter taste. Two of the studies used extemporaneously prepared ketamine capsules (Rabben et al., 1999; Vick and Lamer, 2001). In most of the evaluated studies pain assessment was performed with a visual analogue scale (VAS) or numeric rating scale (NRS). Measurement outcomes were expressed as a reduction of the VAS score in points or in percentages. However, especially in the case reports, pain relief was not always objectified by VAS or NRS. In the randomized controlled trial where a combination of oral ketamine and morphine is compared to morphine alone, both the VAS scores and the daily morphine dose were evaluated (Lauretti et al., 1999). VAS scores were similar between the two groups, but the daily morphine consumption was significantly reduced in the ketamine group. Opioid reduction is also observed in other studies (Vick and Lamer, 2001; Fitzgibbon et al., 2002; Furuhashi-Yonaha et al., 2002; Okon, 2007). There is an inverse relation between the number of included patients in a study and the claimed efficacy of ketamine. About 90% of the case reports present positive results about the efficacy of ketamine, while the larger comparative controlled trials show an efficacy of approximately 25%.

### 3.3. Adverse effects

A high number of withdrawals due to adverse effects were seen. In a study with 21 patients with neuropathic pain, 10 patients withdrew after a run-in open-dose escalation period (Haines and Gaines, 1999). A similar drop-out rate was seen in a non-comparative trial, despite good pain relief in half of the patients who withdrew (Enarson et al., 1999).

The most frequently observed adverse effects were effects on the central nervous system, such as sedation, somnolence, dizziness, sensory illusions, hallucinations, nightmares, dissociative feeling and blurred vision. The psychotomimetic adverse effects, such as hallucinations, were considered the most disturbing. One case report describes a patient with hepatocellular carcinoma and severe hepatic disease. The patient developed serious adverse

effects (e.g. hallucinations and paranoid ideation) starting after a single oral dose of 75 mg ketamine, which resolved quickly (Friedman et al., 2000). The authors suggest that the cause could be high peak plasma levels of ketamine due to an impaired first-pass metabolism. Patients also mentioned gastrointestinal adverse effects, such as nausea, vomiting, anorexia and abdominal pain. One patient developed a gastric ulcer, although the association with ketamine use remained unclear (Klepstad and Borchgrevink, 1997). Rabben et al. (1999) described qualitatively similar adverse effects in patients treated with intramuscularly (0.4 mg/kg) compared to orally (4 mg/kg) administered ketamine, but there were fewer side-effects in the latter group. Disturbing adverse effects disappeared in some patients when the dosage was reduced (Lauretti et al., 1999; Vick and Lamer, 2001; Okon, 2007). Kannan et al. (2002) observed an improvement of the drowsiness in some patients after 2 weeks of treatment. Also, hypnotics and haloperidol were used to prevent or to treat adverse effects of ketamine with variable success (Fisher and Hagen, 1999; Rabben and Oye, 2001; Vick and Lamer, 2001; Fitzgibbon et al., 2002; Furuhashi-Yonaha et al., 2002; Villanueva-Perez et al., 2007).

The duration of treatment was often limited due to adverse effects. Some patients who experienced good pain relief continued to take oral ketamine for several months up to a maximum of more than one year for a few patients (Enarson et al., 1999; Furuhashi-Yonaha et al., 2002; Sakai et al., 2004). No adverse effects caused by long-term treatment were described. A slight progression of pain was seen in one patient after a treatment of 4–5 months, but it is unclear if progression of disease or tolerance to ketamine played a role (Villanueva-Perez et al., 2007). Cognitive impairment and psychological wellbeing were not studied. One case series ( $N = 32$ ) is included which specifically studied the side-effects of ketamine in the long-term treatment (3 months) of neuropathic pain (Cvrcek, 2008). During the entire study period blood pressure values and heart rate remained normal. Clinical chemical parameters measured before and at the end of the study did not show any differences in liver enzymes and other parameters. The electroencephalograph performed at 3 months did not show epileptogenic activity. Differences in adverse effects over time were not specifically mentioned.

## 4. Discussion and conclusions

Evidence on the effect of oral ketamine in chronic pain is limited and the quality of the studies is not very high. The majority of the included studies were non-comparative trials or case reports. The evidence that is available shows that chronic pain patients can have limited benefit from the use of oral ketamine. The dosages that are recommended and the adverse effects that can be expected are discussed below in more detail, resulting in some advice for clinical practice.

### 4.1. Optimal dosage of oral ketamine

The range in effective dosages of orally administered ketamine varies extensively between patients. There seems to be no clear dose–response relation when clinical data are observed. Variability in hepatic metabolism resulting in an increased or reduced bioavailability and variance in plasma levels of norketamine can lead to intra-individual variability. The pharmacokinetic studies performed in healthy volunteers did not show large differences, although only a small number of participants were included (Grant et al., 1981; Clements et al., 1982). It is likely that the variation in dose response and efficacy can be explained by the anti-hyperalgesic effect in low dosages and the anti-nociceptive effect in higher



dosages (Persson, 2008) and perhaps other, yet unknown, mechanisms.

Several case reports describe patients switching from a subcutaneous continuous infusion to an effective oral dosage of ketamine. Considering the substantial differences seen in practice, it is difficult to give a standard conversion factor to calculate an equipotent oral dose. Oral administration of ketamine is associated with higher serum levels of norketamine compared to other routes of administration. The oral bioavailability of ketamine, defined as area under plasma concentration time curve (AUC), after a single oral dose of 0.5 mg/kg is about one fifth of the availability after an intravenous injection. On the other hand, the oral bioavailability of norketamine is similar between the two types of administrations, with much higher peak plasma concentrations (200 ng/ml) reached after oral administration (Grant et al., 1981; Clements et al., 1982). When ketamine is administered as a racemic mixture, both S-norketamine and R-norketamine is formed. S-norketamine is approximately five times weaker than S-ketamine in both binding assay and functional experiments (White et al., 1982; Holtman et al., 2008). Analgesic effects of ketamine were observed with plasma levels of 100–200 ng/ml (sum of S- and R-isomer) following intramuscular and intravenous administration. Effective analgesia following oral dose occurs at much lower concentrations of ketamine (40 ng/ml) (Grant et al., 1981). Considering this and the relatively high plasma concentrations of norketamine reached, norketamine is believed to contribute to the analgesic effects of orally administered ketamine (Bushnell and Craig, 1995; Fisher et al., 2000). Therefore, conversion from parenteral to oral administration in an equipotent dose is complex and is not solely based on a reduced bioavailability. The median conversion rate from subcutaneous to oral ketamine used in the case reports was 1:1. In all the described studies, only the racemic mixture of ketamine was administered. S-ketamine has an analgesic potency which is approximately twice as potent as the racemic mixture (Arendt-Nielsen et al., 1996). In a ketamine-naïve patient, oral administration of ketamine can start with a single dose of 0.5 mg/kg ketamine racemic mixture or 0.25 mg/kg S-ketamine to evaluate the effect on pain relief and the duration of effect. Doses can be increased in steps of 0.5 or 0.25 mg/kg according to the efficacy and adverse effects, respectively. The average dosing frequency of 3–4 times daily found in the clinical studies corresponds well with the elimination half-lives of ketamine (2–3 h) (Grant et al., 1981) and norketamine (4 h) (Product information leaflet, 1999).

#### 4.2. Adverse effects and long-term usage of ketamine

Oral ketamine has been suggested to produce fewer and less severe adverse effects than parenterally administered ketamine, for the following reasons. Smaller (peak) plasma levels of ketamine are reached after oral intake, resulting in fewer or less pronounced adverse effects. After oral intake, the main metabolite norketamine reaches much higher plasma levels due to extensive first-pass metabolism (Grant et al., 1981; Clements et al., 1982). Preclinical animal studies suggest that norketamine might have a more favourable safety profile than ketamine (Holtman et al., 2008). In a crossover placebo-controlled trial by Rabben and colleagues (1999), the adverse effects reported after oral ketamine 4 mg/kg were qualitatively similar but less pronounced compared to ketamine intramuscularly 0.4 mg/kg; it is unclear whether the doses used in this trial were equipotent. The information on adverse effects after long-term use, or development of tolerance to oral ketamine, in chronic pain patients is limited. Ketamine has been used in some patients for more than 1 year without observed tolerance or adverse effects associated with long-term use (Enarson et al., 1999; Furuhashi-Yonaha et al., 2002; Sakai et al., 2004).

After prolonged intrathecal administration of ketamine, neurotoxicity has been found to occur (Vranken et al., 2005). Both a local mechanism of toxicity (because of the intrathecal route) and a mechanism caused by excessive NMDA receptor antagonism may explain this neurotoxicity. The latter mechanism may play a role in prolonged oral administration as well and warrants continued prudence in using long-term oral ketamine.

Studies among recreational ketamine users suggest that frequent ketamine use is associated with impairments in working memory, episodic memory and aspects of executive function, as well as reduction in psychological wellbeing. No association was found with distinct cognitive impairments, although increased levels of delusional and dissociative symptoms were observed. Cognitive impairment may be reversible after stopping ketamine abuse. No impairment was observed in ex-ketamine users (Morgan et al., 2009). Prophylactic use of hypnotics or haloperidol, to prevent adverse effects such as hallucinations, is mentioned in several studies but is not common practice in oral ketamine treatment. Prophylactic medication should not be necessary if the patient starts with a low dose, which is increased slowly depending on clinical and/or adverse effects. If unacceptable adverse effects occur the dose should be reduced.

#### 4.3. Advice for clinical practice

When prescribing oral ketamine for patients with chronic pain, one can encounter a number of practical problems. First of all, ketamine is not approved for this indication and is therefore used off-label (but so are many other medicines with good results). The evidence base for the use of oral ketamine in chronic pain management remains poor and information about long-term side-effects is lacking. Until more research is performed the physician has to weigh the possible risk/benefit ratio for every individual patient.

There is no commercially available oral formulation of ketamine. In the included trials and reports various oral formulations were used. The injection fluid can be taken as an oral solution, and mixed with fruit juice to mask the bitter taste. Some might prefer an extemporaneously prepared oral liquid out of the injection fluid, primarily to improve the taste. Another option is to have an extemporaneous preparation made of ketamine capsules containing ketamine as raw material. Ketamine is not widely available as raw material in pharmaceutical quality. It must be noted that the pharmacokinetic studies with oral ketamine were performed with oral liquid.

Irrespective of which oral formulation is used the question of potential abuse remains important, especially in patients with a history of drug abuse. Ketamine is increasingly being used as a street drug because of its psychotomimetic effects. Ketamine can be bought on the illegal market and is primarily administered through snorting or inhaling lines of the powder form. The powder form can also be obtained by heating the injection fluid. Ketamine abuse in the general population is usually part of a polysubstance disorder (Muetzelfeldt et al., 2008). It remains unclear whether long-term use in chronic pain patients produces dependence.

#### 4.4. Conclusions

Efficacy and long-term adverse effects are insufficiently studied to promote the routine use of oral ketamine in chronic pain management. Some of the studies on oral ketamine show a disappointing success rate, either due to treatment failure or appearance of adverse effects. Wide clinical use of ketamine is limited due to psychotomimetic and other adverse effects. On the other hand, ketamine as an analgesic has proven to be of effect in patients with severe pain who have failed to respond to routine pharmacotherapy. In these patients with intractable pain the use of oral keta-

mine can be beneficial. From that perspective, oral ketamine may have a limited place as add-on therapy in complex chronic pain patients when other therapeutic options have failed.

### Conflicts of interests

The authors have no financial and material support to declare.

### Acknowledgement

The authors like to thank Laraine Visser-Isles (The Language Bureau) for English-language editing.

### References

- Arendt-Nielsen L, Nielsen J, Petersen-Felix S, Schnider TW, Zbinden AM. Effect of racemic mixture and the (S+)-isomer of ketamine on temporal and spatial summation of pain. *Brit J Anaesth* 1996;77:625–31.
- Ben-Ari A, Lewis MC, Davidson E. Chronic administration of ketamine for analgesia. *J Pain Palliat Care Pharmacother* 2007;21:7–14.
- Benitez-Rosario MA, Feria M, Salinas-Martin A, Martinez-Castillo LP, Martin-Ortega JJ. A retrospective comparison of the dose ratio between subcutaneous and oral ketamine. *J Pain Symptom Manage* 2003;25:400–2.
- Bennett GJ. Update on the neurophysiology of pain transmission and modulation: focus on the NMDA-receptor. *J Pain Symptom Manage* 2000;19(Suppl. 1):S2–6.
- Broadley KE, Kurowska A, Tookman A. Ketamine injection used orally. *Palliative Med* 1996;10:247–50.
- Bushnell TG, Craig J. Response of chronic neuropathic pain syndromes to ketamine: a role for norketamine? *Pain* 1995;60:115.
- Clements JA, Nimmo WS, Grant IS. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. *J Pharm Sci* 1982;71:539–42.
- Cvrcek P. Side effects of ketamine in the long-term treatment of neuropathic pain. *Pain Med* 2008;9:253–7.
- Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg FM. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. *Eur J Pharmacol* 1997;333:99–104.
- Eichenberger U, Neff F, Svetcic G, Bjorgo S, Petersen-Felix S, Arendt-Nielsen L, et al. Chronic phantom limb pain: the effects of calcitonin, ketamine, and their combination on pain and sensory thresholds. *Anesth Analg* 2008;106:1265–73.
- Eide PK. Wind-up and the NMDA receptor complex from a clinical perspective. *Eur J Pain* 2000;4:5–15.
- Eide PK, Stubhaug A. Relief of glossopharyngeal neuralgia by ketamine-induced N-methyl-aspartate receptor blockade. *Neurosurgery* 1997;41:505–8.
- Eide K, Stubhaug A, Oye I, Breivik H. Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. *Pain* 1995;61:221–8.
- Enarson MC, Hays H, Woodroffe MA. Clinical experience with oral ketamine. *J Pain Symptom Manage* 1999;17:384–6.
- Fisher K, Hagen NA. Analgesic effect of oral ketamine in chronic neuropathic pain of spinal origin: a case report. *J Pain Symptom Manage* 1999;18:61–6.
- Fisher K, Coderre TJ, Hagen NA. Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. *J Pain Symptom Manage* 2000;20:358–73.
- Fitzgibbon EJ, Hall P, Schroder C, Seely J, Viola R. Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: a strategy for conversion from parenteral to oral ketamine. *J Pain Symptom Manage* 2002;23:165–70.
- Friedman R, Li V, Kueppers F, Atkinson G. Oral ketamine in hepatocellular carcinoma. *Pain Med* 2000;1:181–2.
- Furuhashi-Yonaha A, Iida H, Asano T, Takeda T, Dohi S. Short- and long-term efficacy of oral ketamine in eight chronic-pain patients. *Can J Anaesth* 2002;49:886–7.
- Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. *Brit J Anaesth* 1981;53:805–10.
- Haines DR, Gaines SP. N of 1 randomised controlled trials of oral ketamine in patients with chronic pain. *Pain* 1999;83:283–7.
- Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. *Anesth Analg* 2003;97:1730–9.
- Hoffmann V, Coppejans H, Vercauteren M, Adriaensen H. Successful treatment of postherpetic neuralgia with oral ketamine. *Clin J Pain* 1994;10:240–2.
- Holtman Jr JR, Crooks PA, Johnson-Hardy JK, Hojomat M, Kleven M, Wala EP. Effects of norketamine enantiomers in rodent models of persistent pain. *Pharmacol Biochem Behav* 2008;90:676–85.
- Jensen LL, Handberg G, Helbo-Hansen HS, Skaarup I, Lohse T, Munk T, et al. No morphine sparing effect of ketamine added to morphine for patient-controlled intravenous analgesia after uterine artery embolization. *Acta Anaesthesiol Scand* 2008;52:479–86.
- Kannan TR, Saxena A, Bhatnagar S, Barry A. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. *J Pain Symptom Manage* 2002;23:60–5.
- Kapur N, Friedman R. Oral ketamine: a promising treatment for restless legs syndrome. *Anesth Analg* 2002;94:1558–9.
- Ketanest-S5, solution for injection 5mg/ml Summary of product characteristics. RVG 22550, 19 Jan 1999. Available from: [www.CBG-MEB.nl](http://www.CBG-MEB.nl).
- Kiefer RT, Rohr P, Ploppa A, Dieterich HJ, Grothusen J, Koffler S, et al. Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open-label phase II study. *Pain Med* 2008;9:1173–201.
- Klepstad P, Borchgrevink PC. Four years' treatment with ketamine and a trial of dextromethorphan in a patient with severe post-herpetic neuralgia. *Acta Anaesthesiol Scand* 1997;41:422–6.
- Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. *Anesth Analg* 1998;87:1186–93.
- Kronenberg RH. Ketamine as an analgesic: parenteral, oral, rectal, subcutaneous, transdermal and intranasal administration. *J Pain Palliat Care Pharmacother* 2002;16:27–35.
- Lauretti GR, Lima IC, Reis MP, Prado WA, Pereira NL. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. *Anesthesiology* 1999;90:1528–33.
- Mathisen LC, Skjelbred P, Skoglund LA, Oye I. Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. *Pain* 1995;61:215–20.
- Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. *J Pain Symptom Manage* 2000;20:246–52.
- Morgan CJ, Muettzfeldt L, Curran HV. Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. *Addiction* 2009;104:77–87.
- Muettzfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJ, Curran HV. Journey through the K-hole: phenomenological aspects of ketamine use. *Drug Alcohol Depend* 2008;95:219–29.
- Nikolajsen L, Hansen PO, Jensen TS. Oral ketamine therapy in the treatment of postamputation stump pain. *Acta Anaesthesiol Scand* 1997;41:427–9.
- Okon T. Ketamine: an introduction for the pain and palliative medicine physician. *Pain Physician* 2007;10:493–500.
- Persson J. The ketamine enigma. *Acta Anaesthesiol Scand* 2008;52:453–5.
- Rabben T, Oye I. Interindividual differences in the analgesic response to ketamine in chronic orofacial pain. *Eur J Pain* 2001;5:233–40.
- Rabben T, Skjelbred P, Oye I. Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain. *J Pharmacol Exp Ther* 1999;289:1060–6.
- Sakai T, Tomiyasu S, Ono T, Yamada H, Sumikawa K. Multiple sclerosis with severe pain and allodynia alleviated by oral ketamine. *Clin J Pain* 2004;20:375–6.
- Vick PG, Lamer TJ. Treatment of central post-stroke pain with oral ketamine. *Pain* 2001;92:311–3.
- Villanueva-Perez VL, Cerda-Olmedo G, Samper JM, Minguez A, Monsalve V, Bayona MJ, et al. Oral ketamine for the treatment of type I complex regional pain syndrome. *Pain Pract* 2007;7:39–43.
- Visser E, Schug SA. The role of ketamine in pain management. *Biomed Pharmacother* 2006;60:341–8.
- Vranken JH, Troost D, Wegener JT, Kruis MR, Van der Vegt MH. Neuropathological findings after continuous intrathecal administration of S(+)-ketamine for the management of neuropathic cancer pain. *Pain* 2005;117:231–5.
- White PF, Way WL, Trevor AJ. Ketamine – its pharmacology and therapeutic uses. *Anesthesiology* 1982;56:119–36.